Since targeting amyloid-β has yet to be successful in treating AD [29], alternative approaches that effectively improve damaged neuronal connectivity, such as promoting the BDNF-dependent GR pathway, could help reverse cognitive decline in people with AD and provide a novel avenue of effective therapeutics. This evidence concerns the gene NR3C1 and Alzheimer disease.